Home
Live Updates
Denali Therapeutics Announces Key Anticipated 2024 Milestones and Priorities to Further Advance Its Therapeutics Portfolio for Neurodegeneration and Lysosomal Storage Diseases : comparemela.com
Denali Therapeutics Announces Key Anticipated 2024 Milestones and Priorities to Further Advance Its Therapeutics Portfolio for Neurodegeneration and Lysosomal Storage Diseases
Complete enrollment in Denali-led, late-stage programs for MPS II and ALS, and establish commercial readinessAdvance broad clinical-stage portfolio of seven therapeutic product candidates across...
Related Keywords
Ryan Watts ,
Laura Hansen ,
Nasdaq ,
Exchange Commission ,
Denali Therapeutics Inc ,
Transport Vehicle Enabled ,
Chief Executive Officer ,
Healthcare Conference ,
Enzyme Transport Vehicle ,
Inborn Errors ,
Annual Symposium ,
Frontotemporal Dementia Granulin ,
Protein Transport Vehicle ,
Transport Vehicle ,
Investigational New Drug ,
Transport Vehicle Amyloid ,
South San ,
Private Securities Litigation Reform Act ,
Antibody Transport Vehicle ,
Oligonucleotide Transport Vehicle ,
Quarterly Reports ,
Media Contact ,
Markets ,
comparemela.com © 2020. All Rights Reserved.